These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 18794197)
21. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry]. Ye ZY; Cao YB; Lin TY; Lin HL Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597 [TBL] [Abstract][Full Text] [Related]
22. [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases]. Wang XQ; Zhang LX; Bi CF; Luo TY; Lin L; Min M; Zhao Y; He GX; Feng J; Liu WP Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):302-7. PubMed ID: 20654152 [TBL] [Abstract][Full Text] [Related]
23. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma. Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126 [TBL] [Abstract][Full Text] [Related]
24. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082 [TBL] [Abstract][Full Text] [Related]
25. Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. Lawrie CH; Ballabio E; Soilleux E; Sington J; Hatton CS; Dirnhofer S; Tzankov A Histopathology; 2012 Jul; 61(1):18-25. PubMed ID: 22372580 [TBL] [Abstract][Full Text] [Related]
27. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. Sundram U; Kim Y; Mraz-Gernhard S; Hoppe R; Natkunam Y; Kohler S J Cutan Pathol; 2005 Mar; 32(3):227-34. PubMed ID: 15701085 [TBL] [Abstract][Full Text] [Related]
28. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma]. Yao XX; Wang JF; Wang YH; Gao N Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402 [TBL] [Abstract][Full Text] [Related]
29. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. Saad AG; Grada Z; Bishop B; Abulsayen H; Hassan M; Firpo-Betancourt A; Teruya-Feldstein J; Fraig M; El Jamal SM Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):644-648. PubMed ID: 30179888 [TBL] [Abstract][Full Text] [Related]
30. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Matolcsy A; Chadburn A; Knowles DM Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study. Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD; Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416 [TBL] [Abstract][Full Text] [Related]
32. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841 [TBL] [Abstract][Full Text] [Related]
33. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis]. Soukup J; Krsková L; Mrhalová M; Kodet R; Campr V; Kubácková K; Trnĕný M Cas Lek Cesk; 2003; 142(7):417-22. PubMed ID: 14515445 [TBL] [Abstract][Full Text] [Related]
34. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077 [TBL] [Abstract][Full Text] [Related]
35. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma. Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662 [TBL] [Abstract][Full Text] [Related]
36. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Rossi D; Gaidano G Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786 [TBL] [Abstract][Full Text] [Related]
37. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related]
38. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma]. Li M; Liu CL; Wang XY; Xue XM; Gao ZF Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229 [TBL] [Abstract][Full Text] [Related]
40. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma]. Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]